US bank sees positive risk-reward for AstraZeneca ahead of pivotal heart drug trial

Citi sees the risk-reward balance as favourable for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) ahead of headline results from a pivotal trial of its heart drug...